Glycoursodeoxycholic Acid – 500 mg

Brand:
Cayman
CAS:
64480-66-6
Storage:
-20
UN-No:
Non-Hazardous - /

Glycoursodeoxycholic acid (GUDCA) is a glycine-conjugated form of the secondary bile acid ursodeoxycholic acid (UDCA; Item No. 15121).{48223,34418} It has antioxidant effects in vitro in Barrett’s esophagus cells and primary cultured rat neurons.{34417,34415} GUDCA reduces the levels of inflammatory cytokines and prevents cell death induced by unconjugated bilirubin in an astroglial cell model of neonatal hyperbilirubinemia.{34416} Oral administration of GUDCA (500 mg/kg per day) decreases the severity of symptoms and increases the amount of A. muciniphila, a bacterial species commonly decreased in patients with inflammatory bowel disease (IBD), in a mouse model of colitis.{34418}  

 

Out of stock

SKU: 21698 - Category:

Description

A glycine-conjugated form of ursodeoxycholic acid; has antioxidant effects in vitro in Barrett’s esophagus cells and primary cultured rat neurons; reduces the levels of inflammatory cytokines and prevents cell death induced by unconjugated bilirubin in an astroglial cell model of neonatal hyperbilirubinemia; decreases the severity of symptoms and increases the amount of A. muciniphila in a mouse model of colitis at 500 mg/kg per day


Formal name: N-[(3α,5β,7β)-3,7-dihydroxy-24-oxocholan-24-yl]-glycine

Synonyms:  GUDCA|Ursodeoxycholyl Glycine

Molecular weight: 449.6

CAS: 64480-66-6

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Lipids|Sterol Lipids||Product Type|Biochemicals|Ox Stress Reagents|Antioxidants||Research Area|Cardiovascular System|Blood|Erythrocytes & Hemoglobin||Research Area|Endocrinology & Metabolism|Bile Acids & Microbiome||Research Area|Immunology & Inflammation|Gastric Disease|Ulcerative Colitis||Research Area|Neuroscience||Research Area|Oxidative Stress & Reactive Species|Antioxidant Activity